In 2023, it was estimated that the mortality rate for cancer in Manitoba would be ***** deaths due to per 100,000 population. This statistic displays the estimated mortality rate of cancer in Canada by province in 2023.

In 2023, it was estimated that there would be *** deaths due to cancer among males in Canada between 15 to 29 years. This statistic displays the estimated number of deaths due to all cancer types in Canada by age group and gender in 2023.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

In 2023, it was estimated that there would be 1,300 deaths due to cancer among males in Saskatchewan. This statistic displays the estimated number of cancer deaths in Canada by province and gender in 2023.

During 2023, it was estimated that there would be a total of ***** deaths due to kidney cancer in Canada. Cancer is one of the leading causes of premature death in Canada. This statistic shows the estimated total number of deaths due to cancer in Canada. by cancer type, in 2023.

In 2023, it was estimated that there would be *** deaths due to all cancers among those between 15 and 29 years in Canada. This statistic displays the estimated number of deaths due to all cancers in Canada by age group in 2023.

During 2023, it was estimated that there would be ***** deaths due to kidney cancer among males in Canada. Cancer is one of the leading causes of premature death in Canada. This statistic shows the estimated number of deaths due to cancer in Canada by cancer type and gender in 2023.

In 2023, it was estimated that there would be ***** cancer deaths in Saskatchewan. Cancer is one of the leading causes of premature death in Canada. This statistic displays the estimated number of deaths due to cancer in Canada by province in 2023.

Canada’s In-vitro Diagnostics Market size was valued at USD 3.15 Billion in 2024 and is projected to reach USD 6.23 Billion by 2032, growing at a CAGR of 9% from 2026 to 2032.

Key Market Drivers

Rising Chronic Disease Prevalence and Diagnostic Needs: The rising burden of chronic illnesses, such as diabetes, cardiovascular diseases, and cancer, is driving the demand for in-vitro diagnostics to ensure timely and accurate disease detection and management. According to the Public Health Agency of Canada, chronic disease prevalence has significantly increased between 2020 and 2023. The Canadian Cancer Society reported 233,900 new cancer cases in 2022, highlighting the critical need for advanced diagnostic technologies. Statistics Canada revealed that approximately 44% of Canadians aged 20 and older live with at least one chronic condition, driving substantial demand for in-vitro diagnostic solutions.

This statistic displays age-standardized rate of all cancer types among males in Canada between 1988 and 2019, with a forecast for 2020 to 2023. In 2019, the incidence rate for all cancer cases reached *** per 100,000 population among males. Cancer is one of the leading causes of premature death and almost half the individuals in Canada will develop this disease during their lifetime.

In 2022/23, around 95 percent of cancer care settings in Canada offered smoking cessation support. The share of cancer care settings offering smoking cessation support has increased significantly over the past decade. This statistic shows the percentage of cancer care settings in Canada that offered smoking cessation support from 2012 to 2023.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

In 2020, the mortality rate for lung cancer was **** per 100,000 population among males in Canada. This statistic displays the age-standardized mortality rate of lung cancers among males in Canada between 1988 and 2020, with forecasts from 2021 to 2023.

This statistic displays the age-standardized mortality rate of all cancer among males in Canada between 1988 and 2020, with forecasts from 2021 to 2023. In 1990, the mortality rate for all cancer reached ***** per 100,000 population among males.

Cancer mortality rates in Canada

The mortality rate due to cancer in Canada has steadily declined over the last decades and the trend is expected to continue. The rate of male deaths per 100,000 population had fallen to around *** deaths per 100,000 population in 2020. Cancer mortality rate in females is estimated to reach around *** deaths per 100,000 population in 2023. There is also some variance in mortality rates among genders based on the type of cancer. The mortality rate for lung cancer among men is about ** deaths per 100,000 and ** deaths per 100,000 in women. Men are generally found to have a higher frequency of overall cancer diagnoses than women, including most types of cancers.

The five-year survival rate for most men also tended to be lower than for women. Based on cancer sites, it has been hypothesized that differences in genders such as tobacco smoking, viral infections, hormones, and metal toxicity may be one of the major causes of discrepancies in mortality rates. In 2023, there will be an estimated ****** cancer cases among Canadians between ** and ** years of age. About ** percent of new cancer cases were located in Europe and ** percent of cases located in North America in 2020.

Discover the booming Canadian pharmaceutical market! This in-depth analysis reveals a $2.5 Billion+ market with a projected CAGR of approximately 4.7%, driven by an aging population and rising chronic disease prevalence. Explore key trends, leading companies (Johnson & Johnson, Novartis, Pfizer), and future growth opportunities in this lucrative sector. Recent developments include: October 2023: Panacea Biotec launched Paclitaxel protein-bound particles for injectable suspension (albumin-bound), which is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer, and adenocarcinoma of the pancreas in the Canadian market through its strategic partner, Apotex Inc. of Canada., March 2023: Natco Pharma introduced a generic version of the cancer drug Pomalidomide Capsules in Canada. It is the first generic alternative to Celgene Corporation’s Pomalyst brand in the country, approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of multiple myeloma in adults.. Key drivers for this market are: Rising Geriatric Population, Rising Incidence of Chronic Disease. Potential restraints include: Rising Geriatric Population, Rising Incidence of Chronic Disease. Notable trends are: The Alimentary Tract and Metabolism Segment is Expected to Register Significant Growth Over the Forecast Period.

The incidence rate of all cancers in Manitoba was estimated to be 532 cases per 100,000 population among males in 2023. This statistic displays the estimated incidence rate of cancers among males in Canada by province, as of 2023.

In 2023, it was estimated that there would be **** new stomach cancer cases among males in Canada per 100,000 population. This statistic displays the estimated rate of new cancer cases in Canada by cancer type and gender in 2023.

Canada Clinical Nutrition Market size was valued at USD 2.1 Billion in 2024 and is projected to reach USD 3.5 Billion by 2032, growing at a CAGR of 6.6% from 2026 to 2032. Key Market Drivers:Aging Population: As per Statistics Canada, the number of Canadians aged 65 and up reached 7.3 million in 2023, with projections indicating that this figure will rise to 9.8 million by 2031. Healthcare spending on nutritional support for this demographic increasing by 27% between 2021 and 2023.Rising Chronic Disease Prevalence: The Public Health Agency of Canada reports that 44% of Canadian adults now have at least one chronic condition requiring nutritional management, with diabetes affecting approximately 3.8 million Canadians in 2023, up from 3.2 million in 2020.

This statistic displays the age-standardized rate of lung cancer among males in Canada between 1988 and 2019, with a forecast for 2020 to 2023. In 2023, the incidence rate for lung cancer cases was predicted to drop to ** per 100,000 population among males.

For 2023, it was estimated that there would be 5,700 new breast cancer cases among those between 50 and 59 years old in Canada. This statistic displays the estimated number of new breast cancer cases in Canada among females by age group in 2023.